237 related articles for article (PubMed ID: 32868877)
1. The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy.
Murray AS; Hyland TE; Sala-Hamrick KE; Mackinder JR; Martin CE; Tanabe LM; Varela FA; List K
Oncogene; 2020 Oct; 39(41):6421-6436. PubMed ID: 32868877
[TBL] [Abstract][Full Text] [Related]
2. TMPRSS13 promotes cell survival, invasion, and resistance to drug-induced apoptosis in colorectal cancer.
Varela FA; Foust VL; Hyland TE; Sala-Hamrick KE; Mackinder JR; Martin CE; Murray AS; Todi SV; List K
Sci Rep; 2020 Aug; 10(1):13896. PubMed ID: 32807808
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of the type II transmembrane serine protease, TMPRSS13, in hepatocyte growth factor activator inhibitor-1 and -2-mediated cell-surface localization.
Murray AS; Varela FA; Hyland TE; Schoenbeck AJ; White JM; Tanabe LM; Todi SV; List K
J Biol Chem; 2017 Sep; 292(36):14867-14884. PubMed ID: 28710277
[TBL] [Abstract][Full Text] [Related]
4. Strong expression association between matriptase and its substrate prostasin in breast cancer.
Bergum C; Zoratti G; Boerner J; List K
J Cell Physiol; 2012 Apr; 227(4):1604-9. PubMed ID: 21678412
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
6. Posttranslational modifications of serine protease TMPRSS13 regulate zymogen activation, proteolytic activity, and cell surface localization.
Martin CE; Murray AS; Sala-Hamrick KE; Mackinder JR; Harrison EC; Lundgren JG; Varela FA; List K
J Biol Chem; 2021 Oct; 297(4):101227. PubMed ID: 34562451
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Ras Disrupts Epithelial Integrity by Activating the Transmembrane Serine Protease Hepsin.
Tervonen TA; Pant SM; Belitškin D; Englund JI; Närhi K; Haglund C; Kovanen PE; Verschuren EW; Klefström J
Cancer Res; 2021 Mar; 81(6):1513-1527. PubMed ID: 33461973
[TBL] [Abstract][Full Text] [Related]
8. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
9. TMPRSS13 deficiency impairs stratum corneum formation and epidermal barrier acquisition.
Madsen DH; Szabo R; Molinolo AA; Bugge TH
Biochem J; 2014 Aug; 461(3):487-95. PubMed ID: 24832573
[TBL] [Abstract][Full Text] [Related]
10. TMPRSS13 promotes the cell entry of swine acute diarrhea syndrome coronavirus.
Han Y; Ma Y; Wang Z; Feng F; Zhou L; Feng H; Ma J; Ye R; Zhang R
J Med Virol; 2024 Jun; 96(6):e29712. PubMed ID: 38808555
[TBL] [Abstract][Full Text] [Related]
11. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
12. The combination of thymoquinone and paclitaxel shows anti-tumor activity through the interplay with apoptosis network in triple-negative breast cancer.
Şakalar Ç; İzgi K; İskender B; Sezen S; Aksu H; Çakır M; Kurt B; Turan A; Canatan H
Tumour Biol; 2016 Apr; 37(4):4467-77. PubMed ID: 26500095
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome profiling and protease inhibition experiments identify proteases that activate H3N2 influenza A and influenza B viruses in murine airways.
Harbig A; Mernberger M; Bittel L; Pleschka S; Schughart K; Steinmetzer T; Stiewe T; Nist A; Böttcher-Friebertshäuser E
J Biol Chem; 2020 Aug; 295(33):11388-11407. PubMed ID: 32303635
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.
Obr AE; Kumar S; Chang YJ; Bulatowicz JJ; Barnes BJ; Birge RB; Lazzarino DA; Gallagher E; LeRoith D; Wood TL
Breast Cancer Res; 2018 Nov; 20(1):138. PubMed ID: 30458886
[TBL] [Abstract][Full Text] [Related]
15. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
16. RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC.
Kim SJ; Ju JS; Kang MH; Eun JW; Kim YH; Raninga PV; Khanna KK; Győrffy B; Pack CG; Han HD; Lee HJ; Gong G; Shin Y; Mills GB; Eyun SI; Park YY
Theranostics; 2020; 10(18):7974-7992. PubMed ID: 32724453
[TBL] [Abstract][Full Text] [Related]
17. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
18. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
[TBL] [Abstract][Full Text] [Related]
19. Ibuprofen regulates the expression and function of membrane-associated serine proteases prostasin and matriptase.
Chai AC; Robinson AL; Chai KX; Chen LM
BMC Cancer; 2015 Dec; 15():1025. PubMed ID: 26715240
[TBL] [Abstract][Full Text] [Related]
20. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
